<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">67106</article-id><article-id pub-id-type="doi">10.7554/eLife.67106</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-225345"><name><surname>Kerns</surname><given-names>S Jordan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-225344"><name><surname>Belgur</surname><given-names>Chaitra</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5670-6166</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-36027"><name><surname>Petropolis</surname><given-names>Debora</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-225338"><name><surname>Kanellias</surname><given-names>Marianne</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-225346"><name><surname>Barrile</surname><given-names>Riccardo</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7301-3959</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-225322"><name><surname>Sam</surname><given-names>Johannes</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" id="author-225323"><name><surname>Weinzierl</surname><given-names>Tina</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf8"/></contrib><contrib contrib-type="author" id="author-225324"><name><surname>Fauti</surname><given-names>Tanja</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf9"/></contrib><contrib contrib-type="author" id="author-225325"><name><surname>Freimoser-Grundschober</surname><given-names>Anne</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf10"/></contrib><contrib contrib-type="author" id="author-225326"><name><surname>Eckmann</surname><given-names>Jan</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf11"/></contrib><contrib contrib-type="author" id="author-225327"><name><surname>Hage</surname><given-names>Carina</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf12"/></contrib><contrib contrib-type="author" id="author-225328"><name><surname>Geiger</surname><given-names>Martina</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf13"/></contrib><contrib contrib-type="author" id="author-225318"><name><surname>Ng</surname><given-names>Patrick Ray</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4566-9173</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf14"/></contrib><contrib contrib-type="author" id="author-225317"><name><surname>Tien-Street</surname><given-names>William</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf15"/></contrib><contrib contrib-type="author" id="author-151817"><name><surname>Manatakis</surname><given-names>Dimitris V</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf16"/></contrib><contrib contrib-type="author" id="author-225329"><name><surname>Micallef</surname><given-names>Virginie</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf17"/></contrib><contrib contrib-type="author" id="author-225330"><name><surname>Gerard</surname><given-names>Regine</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf18"/></contrib><contrib contrib-type="author" id="author-225331"><name><surname>Bscheider</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf19"/></contrib><contrib contrib-type="author" id="author-225332"><name><surname>Breous-Nystrom</surname><given-names>Ekaterina</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf20"/></contrib><contrib contrib-type="author" id="author-225333"><name><surname>Schneider</surname><given-names>Anneliese</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="conf21"/></contrib><contrib contrib-type="author" id="author-225334"><name><surname>Giusti</surname><given-names>Anna Maria</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="conf22"/></contrib><contrib contrib-type="author" id="author-225335"><name><surname>Bertinetti-Lapatki</surname><given-names>Cristina</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf23"/></contrib><contrib contrib-type="author" id="author-225319"><name><surname>Grant</surname><given-names>Heather Shannon</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf24"/></contrib><contrib contrib-type="author" id="author-225336"><name><surname>Roth</surname><given-names>Adrian B</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="conf25"/></contrib><contrib contrib-type="author" id="author-225321"><name><surname>Hamilton</surname><given-names>Geraldine A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf26"/></contrib><contrib contrib-type="author" id="author-225337"><name><surname>Singer</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf27"/></contrib><contrib contrib-type="author" id="author-225320"><name><surname>Karalis</surname><given-names>Katia</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf28"/></contrib><contrib contrib-type="author" id="author-225339"><name><surname>Moisan</surname><given-names>Annie</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf29"/></contrib><contrib contrib-type="author" id="author-225340"><name><surname>Bruenker</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-225341"><name><surname>Klein</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf30"/></contrib><contrib contrib-type="author" id="author-225342"><name><surname>Bacac</surname><given-names>Marina</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf31"/></contrib><contrib contrib-type="author" corresp="yes" id="author-225343"><name><surname>Gjorevski</surname><given-names>Nikolce</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf32"/></contrib><contrib contrib-type="author" corresp="yes" id="author-224580"><name><surname>Cabon</surname><given-names>Lauriane</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8472-2227</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="fn" rid="conf33"/></contrib><aff id="aff1"><institution content-type="dept">Research and Development</institution>, <institution>Emulate Inc</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Cell Biology and Infection</institution>, <institution>Emulate Inc</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Research and Development</institution>, <institution>Emulate Inc.</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Pharmacology</institution>, <institution>Roche pRED</institution>, <addr-line><named-content content-type="city">Schlieren</named-content></addr-line>, <country>Switzerland</country></aff><aff id="aff5"><institution content-type="dept">Oncology</institution>, <institution>Roche pRED</institution>, <addr-line><named-content content-type="city">Schlieren</named-content></addr-line>, <country>Switzerland</country></aff><aff id="aff6"><institution content-type="dept">Pharmacology</institution>, <institution>Roche pRED</institution>, <addr-line><named-content content-type="city">Penzberg</named-content></addr-line>, <country>Germany</country></aff><aff id="aff7"><institution content-type="dept">Pharmaceutical Sciences</institution>, <institution>Roche pRED</institution>, <addr-line><named-content content-type="city">Basel</named-content></addr-line>, <country>Switzerland</country></aff><aff id="aff8"><institution content-type="dept">Pharmaceutical Sciences</institution>, <institution>Roche pRED</institution>, <addr-line><named-content content-type="city">Schlieren</named-content></addr-line>, <country>Switzerland</country></aff><aff id="aff9"><institution content-type="dept">Pharma Development</institution>, <institution>Roche pRED</institution>, <addr-line><named-content content-type="city">Basel</named-content></addr-line>, <country>Switzerland</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-179857"><name><surname>Ho</surname><given-names>Ping-Chih</given-names></name><role>Reviewing editor</role><aff><institution>Ludwig Institute for Cancer Research</institution>, <country>Switzerland</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>nikolche.gjorevski@roche.com</email> (NG);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>lauriane.cabon@roche.com</email> (LC);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>11</day><month>08</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e67106</elocation-id><history><date date-type="received"><day>31</day><month>01</month><year>2021</year></date><date date-type="accepted"><day>10</day><month>08</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Kerns et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Kerns et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-67106-v1.pdf"/><abstract><p>Traditional drug safety assessment often fails to predict complications in humans, especially when the drug targets the immune system. Here, we show the unprecedented capability of two human Organs-on-Chips to evaluate the safety profile of T-cell bispecific antibodies (TCBs) targeting tumor antigens. Although promising for cancer immunotherapy, TCBs are associated with an on-target, off-tumor risk due to low levels of expression of tumor antigens in healthy tissues. We leveraged in vivo target expression and toxicity data of TCBs targeting folate receptor 1 (FOLR1) or carcinoembryonic antigen (CEA) to design and validate human immunocompetent Organs-on-Chips safety platforms. We discovered that the Lung-Chip and Intestine-Chip could reproduce and predict target-dependent TCB safety liabilities, based on sensitivity to key determinants thereof, such as target expression and antibody affinity. These novel tools broaden the research options available for mechanistic understandings of engineered therapeutic antibodies and assessing safety in tissues susceptible to adverse events.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><funding-statement>The authors declare that there was no funding for this work.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>S Jordan Kerns, Is a current employee of and hold equity interests or options to obtain equity interests in Emulate Inc.Is an inventor on a patent application (P16451EP00/16/912,391) submitted by Hoffmann-LaRoche and Emulate that covers 'Method for Assessing a Compound Interacting with a Target on Epithelial Cells'.</p></fn><fn fn-type="conflict" id="conf3"><p>Chaitra Belgur, Is a former employee of and hold equity interests or options to obtain equity interests in Emulate Inc.Is an inventor on a patent application (P16451EP00/16/912,391) submitted by Hoffmann-LaRoche and Emulate that covers 'Method for Assessing a Compound Interacting with a Target on Epithelial Cells'.</p></fn><fn fn-type="conflict" id="conf4"><p>Debora Petropolis, Is a former employee of and hold equity interests or options to obtain equity interests in Emulate Inc.Is an inventor on a patent application (P16451EP00/16/912,391) submitted by Hoffmann-LaRoche and Emulate that covers Method for Assessing a Compound Interacting with a Target on Epithelial Cells,.</p></fn><fn fn-type="conflict" id="conf5"><p>Marianne Kanellias, Is a current or former employee of and hold equity interests or options to obtain equity interests in Emulate Inc..</p></fn><fn fn-type="conflict" id="conf6"><p>Riccardo Barrile, Is a former employee of and hold equity interests or options to obtain equity interests in Emulate Inc.Is an inventor on a patent application (P16451EP00/16/912,391) submitted by Hoffmann-LaRoche and Emulate that covers ,Method for Assessing a Compound Interacting with a Target on Epithelial Cells'.</p></fn><fn fn-type="conflict" id="conf7"><p>Johannes Sam, Employment, patents and ownership of stock with Roche..</p></fn><fn fn-type="conflict" id="conf8"><p>Tina Weinzierl, Employment, patents and ownership of stock with Roche..</p></fn><fn fn-type="conflict" id="conf9"><p>Tanja Fauti, Employment, patents and ownership of stock with Roche..</p></fn><fn fn-type="conflict" id="conf10"><p>Anne Freimoser-Grundschober, Employment, patents and ownership of stock with Roche..</p></fn><fn fn-type="conflict" id="conf11"><p>Jan Eckmann, Employment, patents and ownership of stock with Roche..</p></fn><fn fn-type="conflict" id="conf12"><p>Carina Hage, Employment and ownership of stock with Roche..</p></fn><fn fn-type="conflict" id="conf13"><p>Martina Geiger, Employment, patents and ownership of stock with Roche..</p></fn><fn fn-type="conflict" id="conf14"><p>Patrick Ray Ng, is a former employee of and hold equity interests or options to obtain equity interests in Emulate Inc..</p></fn><fn fn-type="conflict" id="conf15"><p>William Tien-Street, is a current employee of and hold equity interests or options to obtain equity interests in Emulate Inc..</p></fn><fn fn-type="conflict" id="conf16"><p>Dimitris V Manatakis, Is a current employee of and hold equity interests or options to obtain equity interests in Emulate Inc..</p></fn><fn fn-type="conflict" id="conf17"><p>Virginie Micallef, Employment and ownership of stock with Roche..</p></fn><fn fn-type="conflict" id="conf18"><p>Regine Gerard, Employment and ownership of stock with Roche..</p></fn><fn fn-type="conflict" id="conf19"><p>Michael Bscheider, Employment and ownership of stock with Roche..</p></fn><fn fn-type="conflict" id="conf20"><p>Ekaterina Breous-Nystrom, Employment and ownership of stock with Roche..</p></fn><fn fn-type="conflict" id="conf21"><p>Anneliese Schneider, Employment, patents and ownership of stock with Roche..</p></fn><fn fn-type="conflict" id="conf22"><p>Anna Maria Giusti, Employment, patents and ownership of stock with Roche..</p></fn><fn fn-type="conflict" id="conf23"><p>Cristina Bertinetti-Lapatki, Is an inventor on a patent application (P16451EP00/16/912,391) submitted by Hoffmann-LaRoche and Emulate that covers 'Method for Assessing a Compound Interacting with a Target on Epithelial Cells'. Employment, patents and ownership of stock with Roche..</p></fn><fn fn-type="conflict" id="conf24"><p>Heather Shannon Grant, Is a former employee of and hold equity interests or options to obtain equity interests in Emulate Inc.Is an inventor on a patent application (P16451EP00/16/912,391) submitted by Hoffmann-LaRoche and Emulate that covers 'Method for Assessing a Compound Interacting with a Target on Epithelial Cells'.</p></fn><fn fn-type="conflict" id="conf25"><p>Adrian B Roth, Is an inventor on a patent application (P16451EP00/16/912,391) submitted by Hoffmann-LaRoche and Emulate that covers 'Method for Assessing a Compound Interacting with a Target on Epithelial Cells'. Employment, patents and ownership of stock with Roche..</p></fn><fn fn-type="conflict" id="conf26"><p>Geraldine A Hamilton, Is a current or former employee of and hold equity interests or options to obtain equity interests in Emulate Inc.Is an inventor on a patent application (P16451EP00/16/912,391) submitted by Hoffmann-LaRoche and Emulate that covers 'Method for Assessing a Compound Interacting with a Target on Epithelial Cells'.</p></fn><fn fn-type="conflict" id="conf27"><p>Thomas Singer, Employment, patents and ownership of stock with Roche..</p></fn><fn fn-type="conflict" id="conf28"><p>Katia Karalis, Is a former employee of and hold equity interests or options to obtain equity interests in Emulate Inc.Is an inventor on a patent application (P16451EP00/16/912,391) submitted by Hoffmann-LaRoche and Emulate that covers 'Method for Assessing a Compound Interacting with a Target on Epithelial Cells'.</p></fn><fn fn-type="conflict" id="conf29"><p>Annie Moisan, is an inventor on a patent application (P16451EP00/16/912,391) submitted by Hoffmann-LaRoche and Emulate that covers Method for Assessing a Compound Interacting with a Target on Epithelial Cells'..</p></fn><fn fn-type="conflict" id="conf30"><p>Christian Klein, Employment, patents and ownership of stock with Roche..</p></fn><fn fn-type="conflict" id="conf31"><p>Marina Bacac, Employment, patents and ownership of stock with Roche..</p></fn><fn fn-type="conflict" id="conf32"><p>Nikolce Gjorevski, is an inventor on a patent application (P16451EP00/16/912,391) submitted by Hoffmann-LaRoche and Emulate that covers Method for Assessing a Compound Interacting with a Target on Epithelial Cells'. Employment, patents and ownership of stock with Roche..</p></fn><fn fn-type="conflict" id="conf33"><p>Lauriane Cabon, is an inventor on a patent application (P16451EP00/16/912,391) submitted by Hoffmann-LaRoche and Emulate that covers Method for Assessing a Compound Interacting with a Target on Epithelial Cells'. Employment, patents and ownership of stock with Roche..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: The animal facility has been accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). All animal studies were performed in accordance with the Federation for Laboratory Animal Science Associations (FELASA). The animal studies were approved by and done under license from the Government of Upper Bavaria (Regierung von Oberbayern; Approval number: Az 55.2.1.54-2532.0-10-16). We have complied with all relevant ethical guidelines and regulations.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>RNA sequencing data have been deposited in the National Center for Biotechnology Information Gene Expression Omnibus (GEO) under accession number GSE175821 and it is currently accessible to reviewers with the token (shihmgyujnanvuh) before its public release on Sep 1st.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Kerns SJ</collab><collab>Manatakis DV</collab></person-group><year iso-8601-date="2021">2021</year><source>Genome-wide transcriptome profiling of human organoids, colon intestine-chip and human alveolus-chips using RNA-seq</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE175821">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE175821</ext-link><comment>NCBI Gene Expression Omnibus, GSE175821</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-67106-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>